Coastline Trust Co Buys 2,350 Shares of Eli Lilly and Company (NYSE:LLY)

Coastline Trust Co boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 14.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,010 shares of the company’s stock after purchasing an additional 2,350 shares during the quarter. Eli Lilly and Company comprises approximately 1.0% of Coastline Trust Co’s investment portfolio, making the stock its 21st biggest position. Coastline Trust Co’s holdings in Eli Lilly and Company were worth $6,528,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Wellington Management Group LLP lifted its position in Eli Lilly and Company by 1.6% during the first quarter. Wellington Management Group LLP now owns 20,324,267 shares of the company’s stock worth $6,979,760,000 after purchasing an additional 314,349 shares during the period. Geode Capital Management LLC lifted its position in Eli Lilly and Company by 1.1% during the first quarter. Geode Capital Management LLC now owns 14,867,424 shares of the company’s stock worth $5,094,159,000 after purchasing an additional 159,964 shares during the period. Morgan Stanley lifted its position in Eli Lilly and Company by 44.1% during the fourth quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock worth $4,411,740,000 after purchasing an additional 3,691,436 shares during the period. Norges Bank bought a new stake in Eli Lilly and Company during the fourth quarter worth about $3,416,206,000. Finally, Moneta Group Investment Advisors LLC lifted its position in Eli Lilly and Company by 102,752.2% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock worth $1,992,374,000 after purchasing an additional 5,440,731 shares during the period. 81.38% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded down $7.24 during trading hours on Wednesday, hitting $592.06. 1,436,021 shares of the company’s stock traded hands, compared to its average volume of 3,011,071. Eli Lilly and Company has a 12-month low of $296.32 and a 12-month high of $601.13. The stock has a market capitalization of $562.04 billion, a price-to-earnings ratio of 83.39, a PEG ratio of 2.36 and a beta of 0.32. The company has a fifty day simple moving average of $504.85 and a 200-day simple moving average of $433.48. The company has a debt-to-equity ratio of 1.63, a current ratio of 1.13 and a quick ratio of 0.87.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $2.11 earnings per share for the quarter, topping the consensus estimate of $1.98 by $0.13. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. The company had revenue of $8.31 billion during the quarter, compared to analyst estimates of $7.58 billion. During the same quarter last year, the firm posted $1.25 EPS. The firm’s revenue for the quarter was up 28.1% on a year-over-year basis. Equities research analysts anticipate that Eli Lilly and Company will post 9.83 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were issued a dividend of $1.13 per share. The ex-dividend date of this dividend was Monday, August 14th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 0.76%. Eli Lilly and Company’s dividend payout ratio is 62.87%.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 27,353 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $454.15, for a total value of $12,422,364.95. Following the transaction, the insider now directly owns 101,446,457 shares of the company’s stock, valued at approximately $46,071,908,446.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CAO Donald A. Zakrowski sold 600 shares of the business’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $546.51, for a total transaction of $327,906.00. Following the transaction, the chief accounting officer now directly owns 5,378 shares of the company’s stock, valued at $2,939,130.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 27,353 shares of the business’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $454.15, for a total value of $12,422,364.95. Following the transaction, the insider now directly owns 101,446,457 shares in the company, valued at $46,071,908,446.55. The disclosure for this sale can be found here. Insiders have sold 1,036,514 shares of company stock valued at $21,107,445,590 in the last ninety days. Company insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. UBS Group boosted their target price on Eli Lilly and Company from $447.00 to $498.00 and gave the stock a “buy” rating in a research note on Wednesday, May 24th. Wells Fargo & Company upped their price objective on Eli Lilly and Company from $500.00 to $615.00 and gave the company an “overweight” rating in a research note on Tuesday, August 8th. The Goldman Sachs Group upped their price objective on Eli Lilly and Company from $385.00 to $470.00 and gave the company a “neutral” rating in a research note on Wednesday, August 9th. Morgan Stanley upped their target price on Eli Lilly and Company from $617.00 to $640.00 and gave the company an “overweight” rating in a report on Tuesday, September 5th. Finally, Royal Bank of Canada upped their target price on Eli Lilly and Company from $490.00 to $580.00 and gave the company an “outperform” rating in a report on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and twenty have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $532.78.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.